Natco Pharma gets favourable ruling for generic Copaxone in US

NEW DELHI: Drug firm Natco Pharma today said it has obtained a favourable ruling from a US Court that paves way for launch of generic Copaxone used for treating multiple sclerosis during May 2014.

"The company is pleased to announce the US Court of Appeals for the Federal Circuit ruling, reversing a district court's finding related to Teva's US Patent for Copaxone," Natco Pharma said in a filing to BSE.

This would mean that Natco could launch the generic Copaxone through its marketing partner Mylan Inc, during May 2014, subject to Food and Drug Administration (FDA) approval, it added.

Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis, Natco Pharma said.

The product is estimated to have clocked revenues of about USD 3.45 billion during 2012 in US market, it added.